The breast biopsy devices market is experiencing strong growth as healthcare systems place greater emphasis on early breast cancer detection, accurate diagnosis, and minimally invasive procedures. Rising breast cancer incidence, expanding screening programs, and increasing awareness of routine mammography are creating demand for biopsy confirmation following abnormal imaging results. At the same time, technological advancements in ultrasound-guided, stereotactic, MRI-guided, and other image-guided procedures are improving targeting accuracy and patient comfort. Healthcare providers are also increasingly adopting outpatient diagnostic procedures that can reduce recovery time and healthcare costs. These trends are supporting the development of more precise, efficient, and patient-friendly breast biopsy solutions.

Market Overview & Projections

The global breast biopsy devices market was valued at USD 1.9 billion in 2025 and is estimated to reach USD 2.1 billion in 2026. The market is projected to reach USD 4.1 billion by 2033, expanding at a CAGR of 9.8% from 2026 to 2033. North America accounted for 44.5% of global revenue in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.

The market is benefiting from the growing number of breast abnormalities identified through screening programs. Once an abnormality is detected through mammography or other imaging methods, biopsy is often required to determine whether the lesion is benign or malignant. This creates consistent demand for biopsy needles, consumables, guidance systems, biopsy drivers, handpieces, and related technologies.

The shift toward minimally invasive diagnosis is another important factor. Core needle biopsy and vacuum-assisted biopsy can provide tissue samples with less discomfort, smaller incisions, and shorter recovery compared with traditional surgical biopsy. These advantages are encouraging hospitals and outpatient centers to invest in modern biopsy equipment.

Download a free sample copy of the Breast Biopsy Devices market report to understand detailed coverage and inclusions in the final report

Market Drivers and Strategic Trends

The increasing global burden of breast cancer remains the primary market driver. As the number of breast cancer cases increases, healthcare providers require reliable diagnostic technologies that can support earlier and more accurate confirmation of suspicious lesions.

Expansion of breast cancer screening programs is also creating new opportunities. Greater access to mammography and advanced breast imaging is increasing the detection of abnormalities that require tissue diagnosis. Governments and healthcare organizations are investing in screening initiatives, particularly among underserved populations, which can increase the long-term demand for biopsy devices.

Another major trend is the growing adoption of minimally invasive procedures. Core needle biopsy provides an established method for collecting tissue samples while reducing patient discomfort and recovery time. Vacuum-assisted biopsy is also gaining attention because it can collect larger tissue samples through fewer insertions and can be useful for selected lesions and microcalcifications.

Image-guided technologies are becoming increasingly important. Ultrasound guidance currently leads the market, while stereotactic, mammography, and MRI-based technologies are improving the ability of clinicians to target lesions accurately. The integration of advanced imaging with automated systems and AI-assisted targeting could further improve procedural consistency.

Key Market Segmentations

• By product, biopsy consumables represented the largest segment in 2025. Consumables generate recurring demand because needles, probes, markers, and procedure-related components are required for individual procedures. The biopsy guidance systems segment is expected to grow rapidly as healthcare providers seek greater targeting precision and improved workflow efficiency.
• By procedure, core needle biopsy (CNB) held the largest share in 2025. Its minimally invasive nature, clinical acceptance, diagnostic reliability, and compatibility with different imaging technologies support its widespread use. Vacuum-assisted biopsy (VAB) is expected to register faster growth because of its ability to obtain larger tissue samples and its expanding use for selected difficult-to-access lesions.
• By guidance technology, ultrasound-guided biopsy dominated in 2025. Ultrasound is widely accessible, does not use ionizing radiation, and allows real-time visualization during procedures. Mammography and stereotactic guidance are also important, particularly for lesions that are difficult to visualize using ultrasound.
• By end use, hospitals accounted for the largest share in 2025 due to their advanced imaging infrastructure, specialized medical teams, and ability to manage complex diagnostic procedures. However, ambulatory surgical centers are expected to grow faster as healthcare systems increasingly favor outpatient procedures, lower costs, and shorter patient stays.

Looking for more specific insights? Customize this report to suite your business needs

Regional Dynamics

North America dominated the breast biopsy devices market in 2025, accounting for 44.5% of global revenue. Strong screening participation, advanced healthcare infrastructure, high adoption of minimally invasive procedures, and the presence of major medical device companies are supporting regional growth. The U.S. represents the largest country-level market.

Asia Pacific is expected to be the fastest-growing regional market from 2026 to 2033. Rising breast cancer awareness, improving healthcare infrastructure, increasing screening coverage, and expanding access to diagnostic technologies are creating significant opportunities. Countries such as China, Japan, India, and South Korea are expected to contribute to regional expansion.

Europe is supported by established healthcare systems, cancer screening initiatives, and increasing demand for advanced diagnostic technologies. Latin America and the Middle East and Africa are also expected to offer opportunities as healthcare infrastructure and access to cancer diagnosis improve.

Key Industry Players

The competitive landscape includes established medical technology companies and specialized biopsy device manufacturers. Key industry players include:

• Hologic, Inc.
• Mammotome (Danaher)
• BD
• Argon Medical
• Merit Medical Systems
• GE HealthCare
• Cook Medical
• MOLLI Surgical (Stryker)
• Planmed Oy
• Metaltronica Spa
• Trivitron Healthcare
• Siemens Healthineers
• Fujifilm Healthcare
• INRAD
• SteryLab
• Resitu Medical
• TransMed7, LLC.

Latest Related Report Explores :

• Breast Cancer Liquid Biopsy Market (2026 - 2033)
• US Breast Biopsy Devices Market (2026 - 2033)
• Breast Cancer Core Needle Biopsy Market (2025 - 2030)
• Prostate Biopsy Devices Market (2026 - 2033)

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.